NUMERAL LTD
(Incorporated in the Republic of Mauritius)
(Registration number: 098177 C1/GBL)
Primary Listing SEM share code: NXII.N0000.
Secondary Listing JSE share code: XII
ISIN: MU0810N005
("the Company" or "Numeral")

CHANGE STATEMENT AND WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT

Shareholders are referred to the cautionary announcement last published on 1 June 2026 and are advised that the Financial Statements contain changes to the previously published Audited Financial Results for the year ended 28 February 2025, which were published on SENS on 1 July 2025 ("**SENS Announcement**"). The changes arose following a detailed pro-active monitoring review of the Annual Financial Statements by the JSE Limited and the Company elected to adopt a number of changes and restate its results for the year ended 28 February 2025, with the enhanced disclosure considered beneficial to shareholders. The restated numbers and notes to the financial statements are included in the Annual Financial Statements for the year ended 28 February 2026, which will be published on or about 15 July 2026.

The following amendments have been made to the previously published group numbers as detailed below, noting that note references refer to the notes in the Annual Financial Statements:

Statement of Financial Position - Group

USD	RESTATED AUDITED Feb 2025	PREVIOUS AUDITED Feb 2025	DIFFERENCES
ASSETS			
Non-current Assets	**3,059,403**	**1,121,815**	**1,937,588**
Deferred tax Note 9	883,458	346,460	536,998
Loan receivables Note 12	680,722	641,700	39,022
Goodwill	430,765	-	430,765
Property, Plant and Machinery Note 13	1,041,290	133,655	907,635
Right of use of Leased Asset	23,168	-	23,168
Current Assets	**1,688,266**	**1,665,178**	**23,088**
Trade and other receivables Note 15	908,365	895,482	12,883
Cash and Cash Equivalents Note 16	199,778	212,662	(12,884)
Inventory Note 14	55,777	32,689	23,088
Loan receivables Note 12	524,345	524,345	-
TOTAL ASSETS	**4,747,669**	**2,786,993**	**1,960,676**
EQUITY			
Capital and Reserves	**235,507**	**(1,992,078)**	**2,227,585**
Share Capital	7,926,898	7,926,898	-
Share premium	20,533,459	20,533,459	-
Accumulated Loss	(27,811,663)	(27,972,928)	161,265
Foreign Currency Translation Reserve	(1,275)	(1,443,782)	1,442,507
Non-controlling interest	(411,911)	(1,035,725)	623,814
LIABILITIES			
Non-Current Liabilities	**3,898,448**	**4,025,833**	**127,385**
Deferred income Note 20	225,625	225,625	-
Borrowings Note 21	3,672,823	3,800,208	127,385
Current Liabilities	**613,715**	**753,238**	**(139,524)**
Trade and other Payables Note 19	554,769	554,769	-
Deferred income Note 20	19,908	19,908	-
Leasehold Liabilities	31,507	-	31,507
Borrowings Note 21	-	171,031	(171,031)
Income tax liabilities Note 9	7,530	7,530	-
TOTAL EQUITY AND LIABILITIES	**4,747,669**	**2,786,993**	**1,960,676**

Details of the restatements in the Statement of Financial Position are set out below

Statement of Financial Position Restatement category	Restated Feb 2025	Published Feb 2025	Nature of error / previous treatment	IFRS correction basis	Affected statements	Affected notes
Accumulated loss NCI	(27,811,663) (411,911)	(27,972,928) (1,035,725)	Incorrect calculation of the at acquisition value of NCI which also impacted on the accumulated loss of the parent	IFRS 10 / IFRS 3	SFP, SCI, SCE, SCF	Notes 1, 2, 3, 11
Goodwill and acquisition accounting	430,765	-	Goodwill for the acquisition of Cryo-Save and Numeral Financial Services had not been calculated.	IFRS 3 / IAS 36	SFP, SCI	Note 11
PPE	1,041,290	133,655	The assets were reflected at book value and not fair values at acquisition date	IFRS 3 / IAS 16 / IFRS 16	SFP, SCI, SCF	Notes 13, 21
ROU and leases	23,168	-	The Laboratory is in a building that is a leased asset, which had not been part of the acquisition and goodwill calculation.	IFRS 3 / IAS 16 / IFRS 16	SFP, SCI, SCF	Notes 13, 21
Deferred tax -Company -Group	 622,612 883,458	 - 346,460	Deferred tax for the Company had not been reflected though mentioned in the published AFS. For the Group the changes in the deferred tax were brought about by the temporary differences of PPE, ROU assets, imputed interest on loans with no interest charges.	IAS 12	SFP, SCI	Note 9
Loans Receivable	680,722	641,700	Classification change - the debit non-current liability was reclassified as a non-current asset.	IAS 1 / IFRS 18	SFP, SCF	Note 12
Trade Receivables and Cash and Cash Equivalents	908,365 199,778	895,482 212,662	Classification change where some trade receivables items were reflected as cash related items.	IAS 1 / IFRS 18	SFP, SCF	Note 12,16
Inventory	55,777	32,689	Inventory was reflected at book value and not fair value.	IFRS 3 / IAS 16 / IFRS 16	IFRS 3 / IAS 16 / IFRS 16	Note 14
ECL and financial instruments	-	-	Calculated but not disclosed.	IFRS 7 / IFRS 9	SFP, SCI	Notes 4, 12, 15
Borrowings and imputed interest	3,672,823	3,800,208	The impact of the calculation of imputed interest on zero-rated loans was reflected as part of the fair value calculation of the loans at acquisition date.	IFRS 9	SFP, SCI, SCF	Notes 21, 22
Lease Liability	31,507	-	The lease liability had not been calculated at the date of acquisition.	IFRS 3 / IAS 16 / IFRS 16	SFP, SCI, SCF	Note 22

Statement of Profit and other Comprehensive Income - Group

USD	RESTATED AUDITED Feb 2025	PUBLISHED AUDITED Feb 2025	DIFFERENCES
Revenue Note 5	974,816	1,692,555	(717,739)
Cost of Sales (Note 6)	(198,995)	(368,466)	169,471
Operating Income from Operations (Gross Profit)	**775,821**	**1,324,089**	**(548,268)**
Administrative expenses Note 7	(27,046)	(47,874)	20,828
Other Expenses Note 7	(387,461)	(804,248)	416,787
Expected Credit Losses (ECL)	(19,560)	-	(19,560)
Finance Cost Note 7.1	(289,112)	-	(289,112)
Foreign exchange loss	10,029	(221,932)	231,961
Other Income Note 8	43,541	-	43,541
Finance Income Note 8	53,958	-	53,958
Net Income Before Taxation	**160,170**	**250,035**	**(89,865)**
Taxation Note 9	10,351	(68,101)	78,452
Net Profit/(Loss) After Taxation	**170,521**	**181,934**	**(11,413)**
FCTR	18,637	-	18,637
Total Comprehensive Income for the Period	**189,158**	**181,934**	**(7,224)**
Net profit attributed to:	**170,521**	**181,934**	**(11,413)**
Owners of the parent	151,993	168,786	(16,793)
Non-controlling interests	18,528	13,148	5,380
Total comprehensive income attributed to:	**189,158**	**181,934**	**(7,224)**
Owners of the parent	150,718	168,786	(18,068)
Non-controlling interests	38,440	13,148	25,292

Details of the restatements in the Statement of Profit and other Comprehensive Income are set out below

Statement of Profit and other Comprehensive Income Restatement category	Restated Feb 2025	Published Feb 2025	Nature of error / previous treatment	IFRS correction basis	Affected statements	Affected notes
Revenue and deferred income	974,816	1,692,555	The classification error was corrected where other income had been reflected as part of revenue and a consolidation elimination was not completed.	IFRS 15	SFP, SCI, SCF	Notes 5, 20
Cost of Sales	(198,995)	(368,466)	Classification errors.	IAS 2	SCI	Note 6
Gross profit	775,821	1,324,089	Adjusted due to the classification errors above.	IAS 8.49 / IAS 1.81A / IAS 21.39(c)	SCI	-
Net Income before tax	160,170	250,035	Adjustments due to classification errors above.	IAS 8 / IAS 12	SCI	-
Taxation expense	10,351	(68,101)	Correct application of the deferred tax implications.	IAS 8 / IAS 12	SCI, SFP	Note 9
FCTR / OCI/other consolidation reserves	(1,275)	(1,443,782	FCTR was not calculated, nor reflected as an OCI item. The "other reserves" were eliminated.	IAS 21	OCI, SCE	Note 2.10 / SCE
Administrative Expenses Other expenses Finance costs	(27,046) (407,021) (289,112)	(47,874) (804,248) -	Classification errors, and reflecting finance costs separately.	IAS 1 / IFRS 18 / IFRS 9	SCI, SCF	Note 7

Statement of Cash Flows - Group

USD	RESTATED Feb 2025	GROUP Feb 2025	DIFFERENCES
Cash used in operations	-	-	-
Profit for the year	170,521	250,035	(79,514)
Interest Expense	289,112	-	289,112
Interest Income	(53,958)	-	(53,958)
Adjustment for:			
Depreciation for property, plant and equipment	58,441	382,311	(323,870)
Depreciation ROU Leased Asset	7,939	-	7,939
Net (Increase)/Decrease in Deferred Tax Asset	(18,012)	-	(18,012)
Adjustments for Foreign Exchange Differences	(10,029)	-	(10,029)
Consolidation Adjustments	-	(2,145,370)	2,145,370
Cash Flows from Operating Activities before Working Capital			**1,957,038**
Changes in working capital			
Inventory	(27,219)	(32,689)	5,470
Other receivables	(110,930)	(85,482)	784,552
Other payables	(325,922)	364,327	(690,249)
Net Increase/(Decrease) in Deferred Income	(251,018)	-	(251,018)
Cash flows from operating activities after Working Capital	**(271,075)**	**(2,076,868)**	**1,805,793**
Interest Received	33,479	-	33,479
Interest Paid	(204,911)	-	(204,911)
Cash Flows from Operating Activities	**(442,507)**	**(2,076,868)**	**3,543,541**
Cash flows from financing activities	**636,685**	**2,805,194**	**(2,168,509)**
Proceeds from/Repayments of loans from group companies	-	(1,166,045)	1,166,045
Repayments of financial liabilities	(181,165)	-	(181,165)
Repayments on Lease Liability	(27,905)	-	(27,905)
Proceeds from issue of shares	-	-	-
Proceeds from borrowings	845,755	3,971,239	(3,125,484)
Cash flows (used in)/generated from investing activities	**5,296**		**521,263**
Net cash inflow from Acquisition of subsidiary	50,808	-	50,808
Amounts advanced to Biotech Companies	(39,022)	-	(39,022)
Acquisition of property, plant and machinery	(6,490)	(515,967)	509,477
Net cash flow for period under review	**199,475**	**212,359**	**12,884**
Cash and cash equivalents at the beginning of the year	303	303	**-**
Cash and cash equivalents at the end of the year	**199,778**	**212,662**	**12,884**

Statement of Changes in Equity

Statement of Changes in Equity - Restated Feb 2025							
Figures in US Dollars	**Share capital**	**Share premium**	**Accumulated (loss)**	**Consolidated reserves**	**Attributed to equity holders of Group**	**Non-controlling interest**	**Total equity**
Balance at 1 March 2024	**7,926,898**	**20,533,459**	**(27,963,657)**	**-**	**496,700**	**-**	**496,700**
NCI arising at acquisition of Cryo-Save			-	-	-	(450,351)	**(450,351)**
Total Comprehensive income for year	-	-	150,718	(1,275)	150,718	38,440	**189,158**
Balance at 28 February 2025	**7,926,898**	**20,533,459**	**(27,812,939)**	**(1,275)**	**647,418**	**(411,911)**	**235,507**

Statement of Changes in Equity - Published Feb 2025							
Figures in US Dollars	**Share capital**	**Share premium**	**Accumulated (loss)**	**Consolidated reserves**	**Attributed to equity holders of Group**	**Non-controlling interest**	**Total equity**
Balance at 1 March 2024	**7,926,898**	**20,533,459**	**(28,141,714)**	**-**	**318,643**	**(1,048,873)**	**(730,230)**
Profit for the year	-	-	168,786	-	168,786	13,148	**181,934**
Other reserves arising on consolidation	-	-	-	(1,443,782)	(1,443,782)	-	**(1,443,782)**
Balance at 28 February 2025	**7,926,898**	**20,533,459**	**(27,972,928)**	**(1,443,782)**	**(956,353)**	**(1,035,725)**	**(1,992,078)**

Headline earnings per share reconciliation and per share information

USD	Group Restated AUDITED 28-Feb-25	Group Published AUDITED 28-Feb-25
Basic earnings per share	**151,993**	**168 786**
Adjustments to headline earnings:	-	-
Headline earnings per share	**151,993**	**168 786**
Weighted average number of shares (net of treasury shares)	**1,242,500,000**	**1,242,500,000**
Basic and diluted loss per share (USD cents)	0.01223	0.014
Headline loss per share (USD cents)	0.01223	0.014

The issued shares were consolidated on the basis of 1 share for every 10 held during the year under review. Thus, the restated basic and headline cents per share per the Annual Financial Statements will be 0.1223 cents per share.

WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT
Following the publication of the restated results above, the cautionary announcement is hereby withdrawn and shareholders no longer need to exercise caution in dealing in the Company's securities.

Numeral Ltd has its primary listing on the Stock Exchange Mauritius and a secondary listing on the AltX of the JSE.

This notice is issued pursuant to SEM Listing Rule 11.3 and the Mauritian Securities Act 2005. The Board of Directors of Numeral Ltd accepts full responsibility for the accuracy of the information contained in this announcement.

For and on Behalf of the Board
Mauritius
15 July 2026

Executive Directors:
Dave van Niekerk
Neville Graham
Jacobus Botma

Non-Executive Directors:
Mohamed Yusuf Sooklall
Dr Aansa Devi Bedacee
Kevin Evans

JSE Sponsor:
AcaciaCap Advisors Proprietary Limited

Management Company and Company Secretary:
LTS Management Services Limited